Q-omics provides the consensus-scored LMBRD2 profile across patient tissues and cancer cell-line models. LMBRD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LMBRD2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, LMBRD2 protein abundance shows 21,692 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where LMBRD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMBRD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMBRD2 survival associations across molecular data types. LMBRD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMBRD2 RNA expression–survival associations across cancer types. High LMBRD2 expression shows unfavorable associations in UVM, KICH, BLCA and KIRP, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LMBRD2 RNA expression.
This table summarizes LMBRD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LMBRD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMBRD2 shows lower tumor expression in THCA, COAD and READ and higher tumor expression in LUAD, BRCA and LIHC. The THCA box plot shows higher LMBRD2 RNA expression in normal versus tumor tissue (log2 FC = −0.834, t-test p < 0.001).
This table shows molecular features associated with LMBRD2 in patient tissues and cancer cell lines. In patient samples, LMBRD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LMBRD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
